MYGN

Myriad Genetics, Inc.

23.20 USD
+0.29 (+1.27%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Myriad Genetics, Inc. stock is up 8.26% since 30 days ago. The next earnings date is Feb 27, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 31.03% of the previous 28 February’s closed higher than January. In the last 1 Unusual Options Trades, there were 1 CALL. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
11 Jan 16:00 16 Feb, 2024 20.00 CALL 450 89

About Myriad Genetics, Inc.

Myriad Genetics, Inc. develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers.

  • Goldman Sachs
    Tue Jan 30, 08:58
    buy
    confirm
  • Goldman Sachs
    Mon Jan 29, 10:33
    buy
    confirm